QIAGEN and GENCURIX, Inc. announced a new partnership on June 18, 2025, to develop oncology assays for use on the QIAcuityDx platform, QIAGEN's high-performance digital PCR system designed for clinical diagnostics. GENCURIX is the first development partner under QIAGEN’s QIAcuityDx Partnering Program.
This collaboration aims to establish a broad menu of in vitro diagnostic (IVD) assays on the QIAcuityDx Four platform, increasing access to digital PCR diagnostics for oncology testing customers. GENCURIX will apply its expertise in multiplex IVD assay development to create oncology tests for both tissue and liquid biopsy applications.
GENCURIX will be responsible for obtaining and maintaining all necessary regulatory approvals and certifications for the assays. Upon approval, QIAGEN will market these assays through its global commercial infrastructure, leveraging the QIAcuity family's installed base of over 2,700 cumulative placements by the end of 2024.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.